



TECHNICAL MANUAL

Lumit[®] IFN- γ (Human) Immunoassay

Instructions for Use of Products
W6040, W6041 and W6042

Lumit[®] IFN- γ (Human) Immunoassay

All technical literature is available at: www.promega.com/protocols/
 Visit the website to verify that you are using the most current version of this Technical Manual.
 Email Promega Technical Services if you have questions on use of this system: techserv@promega.com

1. Description	2
2. Product Components and Storage Conditions	33
3. Before You Begin	4
4. Direct (No-Transfer) Protocol for Cultured Cells	6
4.A. Cell Plating and Treatment.....	6
4.B. Preparing Human IFN- γ Standard Dilution	6
4.C. Adding 5X Anti-hIFN- γ Antibody Mixture to Assay Wells	8
4.D. Adding Lumit [®] Detection Reagent B to Assay Wells	9
5. Optional Sample Transfer Protocol	10
5.A. Cell Plating and Treatment.....	10
5.B. Preparing Human IFN- γ Standard Dilutions.....	11
5.C. Adding 2X Anti-hIFN- γ Antibody Mixture to Sample Wells	12
5.D. Adding Lumit [®] Detection Reagent B to Sample Wells.....	13
6. Calculating Results	14
7. Representative Data	14
8. Troubleshooting	19
9. Appendix.....	20
9.A. Assessing Cross-Reactivity of Lumit [®] Cytokine Immunoassays	20
9.B. Multiplexing Assays with Lumit [®] IFN- γ (Human) Immunoassay	21
9.C. References	22
9.D. Related Products.....	22
10. Summary of Changes	24

1. Description

The Lumit[®] IFN- γ (Human) Immunoassay^(a,b) is a homogeneous, bioluminescent assay for detecting interferon gamma (IFN- γ) released from cells without the need for sample transfers or wash steps. Secreted by activated CD4+ and CD8+ T cells, $\gamma\delta$ T cells, natural killer (NK) cells and antigen-presenting cells (e.g., macrophages), as well as other cells of the immune system, IFN- γ is a homodimer formed by the noncovalent association of two 17kDa polypeptide subunits (1). A critical player in the innate and adaptive immune system, IFN- γ has important antiviral and immunoregulatory properties, including complex effects on tumor biology (1,2). While IFN- γ -based therapies continue to be of interest for cancer and other therapeutic applications (1), measuring the production of IL-2, IFN- γ and other cytokines in cell culture models is an important component of immunology research and related drug discovery efforts. Indeed, IFN- γ release is a common measure of T cell activation in human peripheral blood mononuclear cell (PBMC) preparations, models reliant on use of purified CD4+ or CD8+ T cells, as well as in the characterization of cell therapies, including CAR-T cells (3).

The Lumit[®] IFN- γ (Human) Immunoassay has been developed for use with cell culture samples. Lumit[®] reagents can be dispensed directly into microplate wells containing cells and culture medium. Alternatively, medium from cell wells can be transferred to a separate plate for analysis. Assay performance with additional sample types must be determined by the user.

The Lumit[®] IFN- γ (Human) Immunoassay is based on NanoLuc[®] Binary Technology (NanoBiT[®]). NanoBiT is a luminescent structural complementation system designed for biomolecular interaction studies (4,5). The system is composed of two subunits, Large BiT (LgBiT; 18kDa) and Small BiT (SmBiT; 11 amino acid peptide), that have been optimized for stability and minimal spontaneous association. In this assay, a sample is incubated with a pair of anti-human IFN- γ monoclonal antibodies covalently labeled with SmBiT or LgBiT. When the labeled antibodies recognize and bind to released IFN- γ , the complementary LgBiT and SmBiT molecules are brought into proximity, thereby reconstituting the NanoBiT[®] enzyme and generating luminescence in the presence of the Lumit[®] substrate. Luminescence generated is directly proportional to the amount of analyte present in the sample.





Figure 1. Assay principle. Primary monoclonal antibodies to human IFN- γ are labeled with SmBiT and LgBiT. In the presence of IFN- γ , SmBiT and LgBiT are brought into close proximity, forming the NanoBiT[®] enzyme. When Lumit[®] Detection Reagent B is added, a bright luminescent signal is generated.



17246MB

Figure 2. Assay protocol. The Lumit® IFN-γ (Human) Immunoassay is performed directly on cells in culture or on medium transferred from the cell culture plate to a new assay plate. The Lumit® Immunoassay protocol does not require wash steps and is complete in 70 minutes.

2. Product Components and Storage Conditions

PRODUCT	SIZE	CAT. #
Lumit® IFN-γ (Human) Immunoassay	100 assays	W6040

Sufficient for 100 assays in 96-well plates; volumes can be adjusted for alternate plate sizes. Includes:

- 30µl Anti-hIFN-γ mAb-SmBiT, 500X
- 30µl Anti-hIFN-γ mAb-LgBiT, 500X
- 25µl Human IFN-γ Standard
- 160µl Lumit® Detection Substrate B
- 3.2ml Lumit® Detection Buffer B

PRODUCT	SIZE	CAT. #
Lumit® IFN-γ (Human) Immunoassay	1,000 assays	W6041

Sufficient for 1,000 assays in 96-well plates; volumes can be adjusted for alternate plate sizes. Includes:

- 300µl Anti-hIFN-γ mAb-SmBiT, 500X
- 300µl Anti-hIFN-γ mAb-LgBiT, 500X
- 25µl Human IFN-γ Standard
- 1.25ml Lumit® Detection Substrate B
- 25ml Lumit® Detection Buffer B



2. Product Components and Storage Conditions (continued)

PRODUCT	SIZE	CAT.#
Lumit® IFN-γ (Human) Immunoassay	5 × 100 assays	W6042

Sufficient for 500 assays in 96-well plates; volumes can be adjusted for alternate plate sizes. Includes:

- 5 × 30μl Anti-hIFN-γ mAb-SmBiT, 500X
- 5 × 30μl Anti-hIFN-γ mAb-LgBiT, 500X
- 25μl Human IFN-γ Standard
- 5 × 160μl Lumit® Detection Substrate B
- 5 × 3.2ml Lumit® Detection Buffer B

Storage Conditions: Store complete kit at less than -65°C upon receipt. Alternatively, store the Human IFN-γ Standard at less than -65°C and all other components at -30°C to -10°C. After thawing, store Human IFN-γ Standard at +2°C to +10°C for up to 1 month. If storing the Human IFN-γ Standard for more than 1 month after thawing, dispense into aliquots and store at less than -65°C. After thawing, store the Anti-hIFN-γ mAb-SmBiT and Anti-hIFN-γ mAb-LgBiT at -30°C to -10°C. After thawing, store Lumit® Detection Buffer B at room temperature. Store Lumit® Detection Substrate B protected from light.

3. Before You Begin

There are two protocols for measuring human IFN-γ. The direct protocol typically achieves higher sensitivity than the transfer protocol and requires less sample manipulation. The optional sample transfer protocol provides flexibility for same well sampling during treatment exposure time course experiments and split-sample analysis for assessment of multiple cytokine levels from the same sample.

Direct (No-Transfer) Protocol for Cultured Cells (Section 4): Measure human IFN-γ directly in cell culture wells. Add 20μl of a 5X antibody mixture to 80μl of cells or IFN-γ standard dilutions in culture medium and incubate for 60 minutes. Following incubation, add 25μl of Lumit® Detection Reagent B and record luminescence.

Optional Sample Transfer Protocol (Section 5): Measure human IFN-γ in medium transferred from treated cell wells. Transfer 50μl of culture medium from cell wells to a separate assay plate. Add 50μl of a 2X antibody mixture to 50μl of transferred sample or standard dilutions and incubate for 60 minutes. Following incubation, add 25μl of Lumit® Detection Reagent B and record luminescence.

Note: Assay volumes are scalable and can be adjusted based on sample sizes. The protocols in Sections 4 and 5 list common volumes for 96- and 384-well plates. Other volumes may be used, maintaining the recommended antibody and detection reagent final concentrations. We recommend using standard tissue culture medium supplemented with 5–10% fetal bovine serum (FBS). Lesser concentrations of FBS may produce higher background (nonanalyte-mediated antibody pairing) and higher replicate variability. The use of medium without phenol red may increase assay sensitivity and reduce inner-filter effects from luminescence quenching.

Reagent Preparation and Storage

Prepare the Human IFN- γ Standard dilution series (Section 4.B or 5.B), the Anti-hIFN- γ Antibody Mixture (Section 4.C or 5.C) and Lumit[®] Detection Reagent B (Section 4.C or 5.C) on the day of use. Do **not** reuse Human IFN- γ Standard dilutions, the Anti-hIFN- γ Antibody Mixture or the Lumit[®] Detection Reagent B.



Use personal protective equipment and follow your institution's safety guidelines and disposal requirements when working with biohazardous materials such as cells and cell culture reagents.

Plate Map

	IFN- γ Standard Curve (pg/ml)*		Test Samples									
	1	2	3	4	5	6	7	8	9	10	11	12
A	10,000	10,000										
B	3,000	3,000										
C	900	900										
D	270	270										
E	81	81										
F	24.3	24.3										
G	7.29	7.29										
H	0	0										

***Note:** The indicated Human IFN- γ Standard dilution series listed above and described in the subsequent protocol directions are only a recommended dilution series.

Materials to Be Supplied by the User

- cells (human-derived)
- culture medium (e.g., RPMI 1640, GIBCO[®] Cat.# 22400-089 + 10% heat-inactivated fetal bovine serum, GIBCO[®] Cat.# A3840001)
- white, multiwell tissue culture plates (solid white or white with clear bottom) compatible with a luminometer (e.g., 96-well Corning[®] Cat.# 3917)
- multichannel pipette or automated pipetting station
- dilution tubes or multichamber, dilution reservoir (e.g., Dilux[®] D-1002)
- reagent reservoir trays (e.g., Midwest Scientific Cat.# RR25)
- plate shaker for mixing multiwell plates
- luminometer capable of reading multiwell plates (e.g., GloMax[®] Discover System, Cat.# GM3000)

4. Direct (No-Transfer) Protocol for Cultured Cells

This protocol describes how to detect IFN- γ released directly in assay wells containing cells and culture medium. For quantitation purposes, a standard curve is generated using an IFN- γ standard diluted in culture medium.

4.A. Cell Plating and Treatment

1. Plate cells into a 96- or 384-well, white (or white with clear bottom) tissue culture plate. Leave columns 1 and 2 empty. Allow cells to attach if using adherent cells.

Note: While the broad dynamic range of the assay offers considerable flexibility for cell number, the optimal number of cells dispensed per well for a specific cell model should be determined empirically. Ensure the maximum level of cytokine released does not exceed the linear range of the detection chemistry. Within that constraint, cell number can be increased to meet the detection requirements of low-level cytokine production. See example cell numbers used for human PBMC in Figures 5, 6, 8 and 9.

2. Treat cells by adding a volume of test agent to each well such that the total volume is as follows:

96-well plate: 80 μ l per well

384-well plate: 20 μ l per well

For example, if 60 μ l of cells are plated per well in a 96-well plate, add 20 μ l of 4X treatment agent in culture medium. Cells are typically treated for 6–24 hours or longer, depending on stimuli, to observe release of significant levels of IFN- γ .


Optional: If manually dispensing into the 384-well assay format, after various additions, briefly centrifuge the microplate (700–900rpm for approximately 10 seconds) then briefly mix with a plate shaker to ensure proper mixing.

4.B. Preparing Human IFN- γ Standard Dilution

Shortly before completing cell treatments, prepare IFN- γ dilutions in the identical culture medium used for cell samples.

Note: If using multiple cell models each requiring different culture medium, separate standard dilution series must be generated in each medium used in the study.

1. Prewarm cell culture medium to room temperature; do not exceed 37°C. Use this prewarmed medium to prepare the initial dilution of Human IFN- γ Standard and all subsequent dilutions. This is crucial for successful standard curve preparation.
2. Thaw the Human IFN- γ Standard at room temperature immediately before use. Once thawed, equilibrate the standard at room temperature for at least 15 minutes before proceeding to the next step in the protocol. This equilibration time is crucial for successful standard curve preparation.
3. Briefly centrifuge the tube before opening, then mix by pipetting.
4. Prepare an initial concentration of 10,000pg/ml human IFN- γ by diluting Human IFN- γ Standard (10 μ g/ml) 1:1,000 in prewarmed cell culture medium. For example, prepare 2,000 μ l of 10,000pg/ml human IFN- γ by adding 2 μ l of Human IFN- γ Standard stock to 1,998 μ l of culture medium (see Figure 3).



17996MA

Figure 3. Human IFN- γ dilution series.

5. Set up seven tubes (or seven chambers in a dilution reservoir) with 350 μ l of culture medium in each.
6. Prepare 3.33-fold serial dilutions of standard. Transfer 150 μ l from the 10,000pg/ml initial human IFN- γ dilution (Step 3) to 350 μ l of culture medium for the second dilution. Mix by pipetting and repeat five times to generate seven standard dilutions with a range of 10,000pg/ml to 7.29pg/ml. The last well or chamber should contain only culture medium as the background control.

Note: Change pipette tips between each dilution step and use aerosol filter tips to avoid analyte carryover.

7. After the cell treatment is complete, add the standard dilutions and background control in duplicate to two columns in the assay plate (see the plate map in Section 3).

96-well plate: Dispense 80 μ l per well.

384-well plate: Dispense 20 μ l per well.

Notes:

- a. Unused Human IFN- γ Standard (10 μ g/ml) can be stored at 4°C for 1 month. If storing the standard for more than 1 month, dispense into aliquots and store at less than -65°C. Avoid multiple freeze-thaw cycles.
- b. We recommend incorporating Human IFN- γ Standard controls on each assay plate for normalization.

4.C. Adding 5X Anti-hIFN- γ Antibody Mixture to Assay Wells

Note: If using multiple cell models each requiring different culture medium, separate 5X Anti-hIFN- γ antibody mixtures must be generated in each medium used in the study.

1. Remove the Anti-hIFN- γ antibodies from storage immediately before use. Thaw if necessary.
Note: Remove Lumit[®] Detection Buffer B from storage at the same time and equilibrate to room temperature if not already thawed. Use a water bath to accelerate buffer warming as necessary. If using the 25ml buffer in Cat.# W6041, you may need to initiate buffer warming further in advance of its use in Section 4.D.
2. Briefly centrifuge the Anti-hIFN- γ antibody tubes before opening, then mix by pipetting.
3. Immediately prior to use, prepare a 5X antibody mixture by diluting both antibodies 1:100 into a single volume of prewarmed culture medium. Pipet to mix the antibody solution. To assay a complete 96- or 384-well plate, including some reagent volume for pipetting loss, prepare the 5X antibody mixture as follows:

Reagent	Volume
culture medium	2,352 μ l
Anti-hIFN- γ mAb-SmBiT	24 μ l
Anti-hIFN- γ mAb-LgBiT	24 μ l

4. Add the 5X Anti-hIFN- γ antibody mixture to wells containing cultured cells or standard dilutions, carefully avoiding cross contamination between wells by changing pipette tips if moving from high to low analyte levels.
96-well plate: Dispense 20 μ l/well of 5X Anti-hIFN- γ antibody mixture to 80 μ l/well of cells or IFN- γ standard dilutions.
384-well plate: Dispense 5 μ l/well of 5X Anti-hIFN- γ antibody mixture to 20 μ l/well of cells or IFN- γ standard dilutions.
5. Briefly mix with a plate shaker (e.g., 10 seconds at 250–350rpm).
6. Incubate for 45 minutes at 37°C in a humidified 5% CO₂ incubator.

4.D. Adding Lumit[®] Detection Reagent B to Assay Wells

While cells are incubating with the Anti-hIFN- γ antibody mixture (Section 4.C), prepare the Lumit[®] Detection Reagent B.

1. Equilibrate the required volume of Lumit[®] Detection Buffer B to room temperature.
2. Remove the Lumit[®] Detection Substrate B from storage and mix. If Lumit[®] Detection Substrate B has collected in the cap or on the sides of the tube, briefly centrifuge.
3. Prepare a 1:20 dilution of Lumit[®] Detection Substrate B in room temperature Lumit[®] Detection Buffer B to create enough volume of Lumit[®] Detection Reagent B for the number of wells to be assayed. To assay a 96- or 384-well assay plate, including some reagent volume for pipetting loss, prepare 5X Lumit[®] Detection Reagent B as follows:

Reagent	Volume
Lumit [®] Detection Buffer B	3,040 μ l
Lumit [®] Detection Substrate B	160 μ l

Notes:

- a. The 1,000 assay size Lumit[®] IFN- γ (Human) Immunoassay (Cat.# W6041) contains 25ml of Lumit[®] Detection Buffer B and 1.25ml of Lumit[®] Detection Substrate B. There is sufficient overfill to prepare Lumit[®] Detection Reagent B for analyzing 5 or 10 plates at one time. If Cat.# W6041 is used for assaying 10 plates individually, mix 2,375 μ l of Lumit[®] Detection Buffer B + 125 μ l of Lumit[®] Detection Substrate B for each plate.
 - b. Once reconstituted, the Lumit[®] Detection Reagent B will lose 10% activity in approximately 3 hours at 20°C. At 4°C, the reconstituted reagent will lose 10% activity in approximately 7 hours.
4. After the incubation in Section 4.C, Step 6, equilibrate the assay plate with cells to room temperature for 15 minutes.
 5. Add room temperature 5X Lumit[®] Detection Reagent B to each assay well of the plate:
96-well plate: Dispense 25 μ l per well.
384-well plate: Dispense 6.25 μ l per well.
 6. Briefly mix with a plate shaker (e.g., 10 seconds at 300–500rpm).
 7. Incubate at room temperature for 3–5 minutes.
 8. Read luminescence.

Note: Assay signal is stable with a half-life of approximately 2 hours, compatible with batch processing of multiple assay plates. We recommend incorporating standard controls on each assay plate for normalization.

5. Optional Sample Transfer Protocol

This protocol describes transfer of sample medium from treated cell wells into a separate assay plate for subsequent cytokine detection, leaving the cells and remaining medium for additional uses. For quantitation purposes, a dilution series of Human IFN- γ Standard prepared in culture medium is used to generate a standard curve.

5.A. Cell Plating and Treatment

1. Plate cells into a 96- or 384-well tissue culture plate. Leave columns 1 and 2 empty. Allow cells to attach if using adherent cells.

Note: While the broad dynamic range of the assay offers considerable flexibility for cell number, the optimal number of cells dispensed per well for a specific cell model should be empirically determined. Ensure that the maximum level of cytokine released does not exceed the linear range of the detection chemistry. Within that constraint, cell number can be increased to meet the detection requirements of low-level cytokine production. See example cell numbers used for human PBMC in Figures 5, 6, 8 and 9.

2. Treat cells by adding a volume of test agent to each well. The final treatment volume is flexible. Typical volumes are:

96-well plate: 100–200 μ l per well.

384-well plate: 25–50 μ l per well.

Optional: If manually dispensing into the 384-well assay format, after various additions, briefly centrifuge the microplate (700–900rpm for approximately 10 seconds) then briefly mix with a plate shaker to ensure proper mixing.

3. After cell treatment is complete, transfer cell medium from each well to the corresponding wells of a separate white assay plate:

96-well plate: Transfer 50 μ l per well.

384-well plate: Transfer 12.5 μ l per well.

Notes:

- a. If lower sample volumes are transferred, dilute with culture medium to 50 μ l for 96-well format and 12.5 μ l for 384-well format, subsequently accounting for sample dilution when calculating actual cytokine concentration released in cell wells.
- b. For enhanced 384-well assay sensitivity, if needed, you can transfer 20 μ l of sample (and standards) to assay wells, then add 5 μ l/well of 5X Anti-hIFN- γ antibody mixture (prepared in Section 4.C).

5.B. Preparing Human IFN- γ Standard Dilutions

Shortly before completing cell treatments, prepare IFN- γ standard dilutions in the identical culture medium used for cell samples.

Note: If using multiple cell models, each requiring different culture medium, separate standard dilution series must be generated in each medium used.

1. Prewarm cell culture medium to room temperature; do not exceed 37°C. Use this prewarmed medium to prepare the initial dilution of Human IFN- γ Standard and all subsequent dilutions. This is crucial for successful standard curve preparation.
2. Thaw the Human IFN- γ Standard at room temperature immediately before use. Once thawed, equilibrate the standard at room temperature for at least 15 minutes before proceeding to the next step in the protocol. This equilibration time is crucial for successful standard curve preparation.
3. Briefly centrifuge the tube before opening, then mix by pipetting.
4. Prepare an initial concentration of 10,000pg/ml human IFN- γ by diluting Human IFN- γ Standard (10 μ g/ml) 1:1,000 in prewarmed cell culture medium. For example, prepare 2,000 μ l of 10,000pg/ml human IFN- γ by adding 2 μ l of the Human IFN- γ Standard stock to 1,998 μ l of culture medium (Figure 3).
5. Set up seven tubes (or seven chambers in a dilution reservoir) with 350 μ l of culture medium in each.
6. Proceed with 3.33-fold serial dilutions of standard. Transfer 150 μ l from the 10,000pg/ml stock to 350 μ l of culture medium for the second dilution. Mix and repeat five times to generate seven standard dilutions with a range of 10,000pg/ml to 7.29pg/ml. The last well or chamber should contain only culture medium as the background control.

Note: Change pipette tips between each dilution step and use aerosol filter tips to avoid analyte carryover.

7. After transferring the culture medium from the treated cell wells to a separate assay plate, add the standard dilutions and background control in duplicate to two columns in the transfer plate (see the plate map in Section 3).

96-well plate: Dispense 50 μ l per well.

384-well plate: Dispense 12.5 μ l per well.

Notes:

- a. Unused Human IFN- γ Standard (10 μ g/ml) can be stored at 4°C for 1 month. If storing the standard for more than 1 month, dispense into aliquots and store at less than -65°C. Avoid multiple freeze-thaw cycles.
- b. We recommend incorporating Human IFN- γ Standard controls on each assay plate for normalization.

5.C. Adding 2X Anti-hIFN- γ Antibody Mixture to Sample Wells

If using multiple cell models each requiring different culture medium, separate 2X Anti-hIFN- γ antibody mixtures must be generated in each medium used in the study.

1. Remove the Anti-hIFN- γ antibodies from storage immediately before use. Thaw if necessary.
Note: Remove Lumit[®] Detection Buffer B from storage at the same time and equilibrate to room temperature if not already thawed. Use a water bath to accelerate thawing as necessary. If using the 25ml buffer in Cat.# W6041, you may need to initiate buffer thawing further in advance of its use in Section 5.D.

2. Briefly centrifuge the Anti-hIFN- γ antibody tubes before opening, then mix by pipetting.
3. Immediately prior to use, prepare a 2X antibody mixture by diluting both antibodies 1:250 into a single volume of prewarmed cell culture medium. Pipet to mix the antibody solution. To assay a complete 96- or 384-well plate, including some reagent volume for pipetting loss, prepare the 2X antibody mixture as follows:

Reagent	Volume
culture medium	5,952 μ l
Anti-hIFN- γ mAb-SmBiT	24 μ l
Anti-hIFN- γ mAb-LgBiT	24 μ l

4. Add the 2X Anti-hIFN- γ antibody mixture to transferred culture medium (samples) or IFN- γ standard dilutions, carefully avoiding cross-contamination between wells by changing pipette tips if moving from high to low analyte levels.
96-well plate: Dispense 50 μ l/well of 2X Anti-hIFN- γ antibody mixture to 50 μ l/well of medium or standard dilutions.
384-well plate: Dispense 12.5 μ l/well of 2X Anti-hIFN- γ antibody mixture to 12.5 μ l/well of medium or standard dilutions.

5. Briefly mix with a plate shaker (e.g., 10 seconds at 250–350rpm).
6. Incubate for 60 minutes at room temperature.
Note: To incubate at room temperature, a HEPES-containing medium will provide best results. Without HEPES, the buffering capacity outside of a CO₂ incubator is limited. The plates can also be incubated at 37°C in a CO₂ incubator if subsequently equilibrated to room temperature prior to addition of detection reagent.

5.D. Adding Lumit[®] Detection Reagent B to Sample Wells

While the samples and standard dilutions are incubating with the Anti-hIFN- γ antibody mixture (Section 5.C), prepare the Lumit[®] Detection Reagent B.

1. Equilibrate the required volume of Lumit[®] Detection Buffer B to room temperature.
2. Remove Lumit[®] Detection Substrate B from storage and mix. If Lumit[®] Detection Substrate B has collected in the cap or on the sides of the tube, briefly centrifuge.
3. Prepare a 1:20 dilution of Lumit[®] Detection Substrate B into room temperature Lumit[®] Detection Buffer B to ensure enough volume of Lumit[®] Detection Reagent B for the number of wells to be assayed. For a 96- or 384-well assay plate, including some excess reagent volume, prepare 5X Lumit[®] Detection Reagent B as follows:

Reagent	Volume
Lumit [®] Detection Buffer B	3,040 μ l
Lumit [®] Detection Substrate B	160 μ l

Notes:

- a. The 1,000 assay size of Lumit[®] IFN- γ (Human) Immunoassay (Cat.# W6041) contains 25ml of Lumit[®] Detection Buffer B and 1.25ml of Lumit[®] Detection Substrate B. There is sufficient overfill to prepare Lumit[®] Detection Reagent B for analyzing 5 or 10 plates at once. If Cat.# W6041 is used for assaying 10 plates individually, mix 2,375 μ l of Lumit[®] Detection Buffer B + 125 μ l of Lumit[®] Detection Substrate B for each plate.
 - b. Once reconstituted, the Lumit[®] Detection Reagent B loses 10% activity in approximately 3 hours at 20°C. At 4°C, the reconstituted reagent loses 10% activity in approximately 7 hours.
4. After the incubation in Section 5.C, Step 6, add room temperature Lumit[®] Detection Reagent B to each assay well of the plate:
96-well plate: Dispense 25 μ l per well.
384-well plate: Dispense 6.25 μ l per well.
 5. Briefly mix with a plate shaker (e.g., 10 seconds at 300–500rpm).
 6. Incubate at room temperature for 3–5 minutes.
 7. Read luminescence.

Note: Assay signal is stable with a half-life of approximately 2 hours, compatible with batch processing of multiple assay plates.

6. Calculating Results

Create a standard curve for the known cytokine concentrations using software (e.g., GraphPad® Prism) capable of nonlinear regression analysis or cubic spline curve fitting.

Subsequently, interpolate the concentration of cytokine in various cell samples. The broad dynamic range of the Lumit® standard curve closely approaches linearity and is well-suited for second- or third-order polynomial regression curve fitting, as well as cubic spline curve fitting. Four-parameter logistic (4PL) curve fitting is also commonly used, but may not be ideal since the broad, linear dynamic range for the Lumit® standard curve is not well-suited for sigmoidal curve fitting (6).

Alternatively, while somewhat less accurate, a Log-Log plot of average RLU (background-subtracted) vs. cytokine standard concentrations can be fit with the Power trendline in Microsoft Excel® (see Section 7) and subsequently used for interpolating the concentration of cytokine release in various cell samples.

7. Representative Data




Figure 4. Standard curve for the Lumit® IFN-γ (Human) Immunoassay. This is a representative standard curve and should not be used for calculation of unknowns. Generate a standard curve on each assay plate to interpolate the cytokine concentration in experimental samples. **Note:** The plotted luminescence values were determined by subtracting background RLU.

7. Representative Data (continued)

Table 1. Assay Precision. Three samples of known concentrations of human IFN- γ were tested 20 times on two plates to assess assay precision. A standard curve was used on each assay plate to interpolate the IFN- γ quantities in each well by using cubic spline fitting with GraphPad® Prism software.

Assay Precision			
Number of Replicates	40	40	40
Expected (pg/ml)	10,000	1,000	100
Mean (pg/ml)	9,630	991	101
Standard Deviation	241	32	3
Percent CV	2.5	3.2	3.1
Average Percent of Expected	96.3	99.1	100.9
Percent Range	86–100	92–110	93–112

Note: The minimal detectable dose (MDD), determined at two standard deviations above background, was 1.1 ± 0.1 pg/ml of hIFN- γ .




Figure 5. Optimization of cell number for Lumit® IFN- γ (Human) Immunoassay performance. Human peripheral blood mononuclear cells (PBMC) pooled from four donors (BioIVT) were plated in RPMI 1640 + 10% heat-inactivated FBS at increasing numbers of cells/well in 96-well plates and treated with 1X Cell Stimulation Cocktail (CSC; Invitrogen Cat.# 00-4970-93) for 6, 24 and 48 hours. 1X CSC is a mixture of 81nM phorbol 12-myristate 13-acetate (PMA) and 1.34 μ M ionomycin. Luminescence measurements obtained by direct reagent addition (Section 4) to stimulated and untreated cell wells were used to calculate signal-to-background values. Stimulated IFN- γ release was reliably observed over a wide range of cell numbers, even as few as 1,000 cells/well.

7. Representative Data (continued)




Figure 6. Lumit[®] detection of IFN- γ released from human peripheral blood mononuclear cells (PBMC). PBMC pooled from four donors (BioIVT) were plated in RPMI 1640 + 10% heat-inactivated FBS at 10,000 cells/well in 96-well plates. Cells were treated with a titration of Cell Stimulation Cocktail (CSC) for 6, 24, or 48 hours. Subsequently, the 5X Anti-hIFN- γ antibody mixture was dispensed to the cell wells and plates incubated for 1 hour before adding Lumit[®] Detection Reagent B. Luminescence readings were analyzed using cubic spline interpolation (GraphPad[®] Prism 8) against the standard curve to determine levels of IFN- γ released. Replicates: n = 3.




Figure 7. Simple detection of IFN-γ release from a complex culture model in response to a biological agent. Purified CD8+ T cells were plated with target Raji B cells and treated with increasing concentrations of the bispecific T cell engager Blincyto®, a therapeutic monoclonal antibody that interacts with CD3 on effector T cells and CD19 on target cells. Consequent to effector cell activation and target cell killing, T cells release immunomodulatory cytokines, including IFN-γ. Direct addition of Lumit® IFN-γ (Human) Immunoassay reagents to this complex culture model enabled simple and rapid determination of cytokine release in response to drug treatment.

7. Representative Data (continued)




Figure 8. Multiple cytokine detection by split-sample analysis via optional sample transfer protocol. Human PBMC were plated in a 96-well plate at 50,000 cells/well in RPMI 1640 + 10% heat-inactivated FBS. Cell wells were treated in quadruplicate in a 100 μ l final volume for 24 hours with either 1X Cell Stimulation Cocktail (CSC; Invitrogen Cat.# 00-4970-93), 2EU/ml lipopolysaccharide (LPS; InvivoGen Cat.# tlr1-3pelps) or 8 μ g/ml R848 (InvivoGen Cat.# tlr1-r848). Subsequently, from each cell well, four 20 μ l sample aliquots were transferred into a white, 384-well assay plate. These split-sample aliquots were individually assayed with different Lumit[®] cytokine immunoassays to determine IL-2, IL-6, IFN- γ and TNF- α levels previously released into the treated cell wells. After adding 5X anti-cytokine antibody mixture (5 μ l) for each assay and incubating for 1 hour at room temperature, 6.25 μ l of Lumit[®] Detection Reagent B was added. Luminescence readings from assay wells were analyzed using cubic spline interpolation (GraphPad[®] Prism 9) against respective standard curves to determine the levels of individual cytokines. Given the nonlytic nature of the assay chemistry, this simple approach for profiling cytokine release can be applied equally to adherent or suspension cell models.

8. Troubleshooting

For questions not addressed here, please contact your local Promega Branch Office or Distributor. Contact information available at: www.promega.com. Email: techserv@promega.com

Symptoms	Causes and Comments
No signal from treated cells	Make sure that human cells are used with the Lumit [®] IFN- γ (Human) Immunoassay. The Lumit [®] IFN- γ (Human) Immunoassay will not effectively detect IFN- γ from other species. In addition to the Human IFN- γ Standard, consider using treated human PBMC as a positive control.
Human IFN- γ standard curve is not linear	The 3.33-fold dilutions should be carefully created without carryover from a higher concentration. We recommend changing aerosol filter pipette tips after each dilution step to prevent carryover. The sensitivity of the assay and the broad linear range (>3 logs) means that any carryover will disrupt the linear range. Also, make sure that no IFN- γ contaminates the background control.
The relative light units (RLU) for the standard curve are low and/or variable	Warm culture medium, Human IFN- γ Standard and Lumit [®] Detection Buffer B to room temperature before use. There may be some variation in RLU due to culture conditions, temperature, etc., but as long as the standard curve is run on the same plate as the test samples under the same conditions, released IFN- γ can be quantitated accurately.

9. Appendix

9.A. Assessing Cross-Reactivity of Lumit® Cytokine Immunoassays

Table 2. Testing Immunoassay Cross-Reactivity. The specificity of Lumit® cytokine immunoassays were assessed against a panel of their respective recombinant standards. Each Lumit® cytokine immunoassay was applied to 10ng/ml of the indicated cytokine standards in triplicate assay wells, in addition to wells containing only medium for background determination. Background luminescence was subtracted prior to normalization of average assay signals with each cytokine to that of the intended target of the Lumit® cytokine immunoassay. For the Lumit® IFN-γ (Human) Immunoassay, signals obtained from the tested cytokines were less than or equal to 0.04% of the signal from human IFN-γ.

Lumit® Cytokine Immunoassay (Percent Assay Control)							
Standard (10ng/ml)	hIL-1β	hIL-2	hIL-4	hIL-6	hIL-10	hIFN-γ	hTNF-α
hIL-1β	100	0.01	0.02	0	0	0.02	0
hIL-2	0	100	0.02	0	0	0.01	0
hIL-4	0.06	0.01	100	0	0.02	0.01	0
hIL-6	0.07	0.02	0.06	100	0.02	0.03	0
hIL-10	0.18	0.03	0.03	0.03	100	0.04	0
hIFN-γ	0.10	0.03	0.03	0.03	0.02	100	0.03
hTNF-α	0.01	0.01	0.02	0.02	0.01	0.03	100

9.B. Multiplexing Assays with Lumit[®] IFN- γ (Human) Immunoassay




Figure 9. Same-well determination of IFN- γ release, cytotoxicity and viability for treated human PBMC. Human PBMC were plated in RPMI 1640 + 10% heat-inactivated FBS at 20,000 cells/well in an all-white 96-well plate and treated at a total volume of 70 μ l with increasing concentrations of Cell Stimulation Cocktail (CSC) for 24 hours. Following treatment, 10 μ l of 10X CellTox[™] Green Reagent (prepared in Assay Buffer as described in the *CellTox[™] Green Cytotoxicity Assay Technical Manual #TM375*) and 20 μ l of 5X Anti-hIFN- γ antibody mixture (Section 4) were added to each well. The assay plate was incubated for 45 minutes at 37°C in a humidified 5% CO₂ incubator prior to measuring fluorescence (RFU) indicating cytotoxicity. The assay plate was allowed to equilibrate to room temperature for 15 minutes before adding 25 μ l of Lumit[®] Detection Reagent B to assess human IFN- γ release. Lastly, 100 μ l of the lytic CellTiter-Glo[®] Reagent was added to each well (as described in the *CellTiter-Glo[®] Luminescent Cell Viability Assay Technical Bulletin #TB288*) and the plate was shaken for 2 minutes at 350rpm, then incubated for 10 minutes before the luminescence signal (RLU) was measured. Luminescence reflects cell viability. **Panel A.** Dose-dependent release of human IFN- γ was observed in response to CSC treatment. **Panel B.** Some degree of increased cytotoxicity and decreased cell viability was observed in response to 24-hour treatment with increasing CSC. **Note:** Maximal cell death provoked by adding a reference cytotoxic agent (50 μ g/ml digitonin) produced fluorescence readings (using the CellTox[™] Green Cytotoxicity Assay, Cat.# G8741) of more than 4,770 RFU while viability signals (shown as luminescence using the CellTiter-Glo[®] Viability Assay, Cat.# G7570) were reduced by more than 94% relative to untreated cells (data not shown).

9.C. References

1. Castro, F. *et al.* (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. *Front. Immunol.* **9**, 847.
2. Schroder, K. *et al.* (2004) Interferon-gamma: an overview of signals, mechanisms and functions. *J. Leukoc. Biol.* **75(2)**, 163–89.
3. Teng, R. *et al.* (2019) Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model. *J. Immunother.* **42**, 33–42.
4. Dixon, A.S. *et al.* (2016) NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem. Biol.* **11**, 400–8.
5. Hwang, B.B. *et al.* (2020) A homogeneous bioluminescent immunoassay to probe cellular signaling pathway regulation. *Commun. Biol.* **3**, 8.
6. Herman, R.A., Scherer, P.N. and Shan, G. (2008) Evaluation of logistic and polynomial models for fitting sandwich-ELISA calibration curves. *J. Immunol. Methods* **339**, 245–58.

9.D. Related Products

Lumit[®] Immunoassays

Product	Size	Cat.#
Lumit [®] FcRn Binding Immunoassay	100 assays	W1151
Lumit [®] HMGB1 (Human/Mouse) Immunoassay	100 assays	W6110
Lumit [®] Human IL-1 β Immunoassay	100 assays	W6010
Lumit [®] IL-2 (Human) Immunoassay	100 assays	W6020
Lumit [®] IL-4 (Human) Immunoassay	100 assays	W6060
Lumit [®] IL-6 (Human) Immunoassay	100 assays	W6030
Lumit [®] IL-10 (Human) Immunoassay	100 assays	W6070
Lumit [®] Mouse IL-1 β Immunoassay	100 assays	W7010
Lumit [®] TNF- α (Human) Immunoassay	100 assays	W6050

Additional sizes available.

Lumit[®] Immunoassay Reagents

Product	Size	Cat.#
Lumit [®] Detection Reagent B*	100 assays	VB4050
Lumit [®] Immunoassay Cellular Systems–Starter Kit	200 assays	W1220
Lumit [®] Immunoassay Labeling Kit*	1 each	VB2500

* Additional sizes available.

Inflammation Assays

Product	Size	Cat. #
Caspase-Glo [®] 1 Inflammasome Assay	10ml	G9951
RealTime-Glo [™] Extracellular ATP Assay	200 assays	GA5010

Additional sizes available.

Cell Viability Assays

Product	Size	Cat. #
CellTiter-Glo [®] 2.0 Cell Viability Assay	10ml	G9241
CellTiter-Glo [®] Cell Viability Assay	10ml	G7570
RealTime-Glo [™] MT Cell Viability Assay	100 reactions	G9711
CellTiter-Fluor [™] Cell Viability Assay	10ml	G6080

Additional sizes available.

Cytotoxicity Assays

Product	Size	Cat. #
LDH-Glo [™] Cytotoxicity Assay	10ml	J2380
CytoTox-Glo [™] Cytotoxicity Assay	10ml	G9290
CellTox [™] Green Cytotoxicity Assay	10ml	G8741

Additional sizes available.

Energy Metabolism and Oxidative Stress Assays

Product	Size	Cat. #
NAD/NADH-Glo [™] Assay	10ml	G9071
NADP/NADPH-Glo [™] Assay	10ml	G9081
ROS-Glo [™] H ₂ O ₂ Assay	10ml	G8820
GSH/GSSG-Glo [™] Assay	10ml	V6611
Lactate-Glo [™] Assay	5ml	J5021
Glucose-Glo [™] Assay	5ml	J6021
Glutamine/Glutamate-Glo [™] Assay	5ml	J8021
Glycerol-Glo [™] Assay	5ml	J3150
Triglyceride-Glo [™] Assay	5ml	J3160
Cholesterol/Cholesterol Ester-Glo [™] Assay	5ml	J3190

Additional sizes available.



9.D. Related Products (continued)

Apoptosis Assays

Product	Size	Cat.#
Caspase-Glo® 3/7 Assay System	2.5ml	G8090
Caspase-Glo® 8 Assay System	2.5ml	G8200
Caspase-Glo® 9 Assay System	2.5ml	G8210
RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay	100 assays	JA1011

Additional sizes available.

10. Summary of Changes

The following changes were made to the 8/24 revision of this document:

1. Step 1 was added and Step 2 updated in Sections 4.B and 5.B.
2. Fonts were updated.
3. Lumit trademark and one patent statement were updated.

^(a)U.S. Pat. Nos. 9,797,889; 9,797,890; 10,107,800; 10,648,971; and other patents and patents pending.

^(b)U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

© 2022–2024 Promega Corporation. All Rights Reserved.

Caspase-Glo, CellTiter-Glo, Lumit, NanoBIT and NanoLuc are registered trademarks of Promega Corporation. CellTiter-Fluor, CellTox, CytoTox-Glo, Ester-Glo, Glucose-Glo, Glutamine/Glutamate-Glo, Glycerol-Glo, GSH/GSSG-Glo, Lactate-Glo, LDH-Glo, NAD/NADH-Glo, NADP/NADPH-Glo, RealTime-Glo, ROS-Glo and Triglyceride-Glo are trademarks of Promega Corporation.

Blinicyto is a registered trademark of Amgen, Inc. Corning is a registered trademark of Corning, Inc. Dilux is a registered trademark of Dilux, L.L.C. Excel and Microsoft are registered trademarks of Microsoft Corporation. GIBCO is a registered trademark of Thermo Fisher Scientific. GraphPad Prism is a registered trademark of GraphPad Software, Inc.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our website for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.